Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to $11024.0.

  • Regen BioPharma's Accounts Payables fell 6938.2% to $11024.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $11024.0, marking a year-over-year decrease of 6938.2%. This contributed to the annual value of $1714.0 for FY2025, which is 9422.29% down from last year.
  • According to the latest figures from Q4 2025, Regen BioPharma's Accounts Payables is $11024.0, which was down 6938.2% from $1714.0 recorded in Q3 2025.
  • Regen BioPharma's 5-year Accounts Payables high stood at $1.3 million for Q1 2021, and its period low was $1714.0 during Q3 2025.
  • For the 5-year period, Regen BioPharma's Accounts Payables averaged around $645565.3, with its median value being $650406.5 (2023).
  • As far as peak fluctuations go, Regen BioPharma's Accounts Payables surged by 1025.92% in 2021, and later plummeted by 9772.64% in 2022.
  • Over the past 5 years, Regen BioPharma's Accounts Payables (Quarter) stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then tumbled by 96.51% to $44183.0 in 2023, then dropped by 18.51% to $36005.0 in 2024, then tumbled by 69.38% to $11024.0 in 2025.
  • Its Accounts Payables was $11024.0 in Q4 2025, compared to $1714.0 in Q3 2025 and $30477.0 in Q2 2025.